Asian Technology and Chipmaking Stocks Slide as AI Spending Concerns Shake Markets 
Fed Near Neutral Signals Caution Ahead, Shifting Focus to Fixed Income in 2026 
Australia’s Under-16 Social Media Ban Sparks Global Debate and Early Challenges 
U.S. Soldiers Killed in ISIS Attack in Palmyra, Syria During Counterterrorism Mission 
Trump Administration Fuel-Efficiency Rollback Could Raise Long-Term Costs for U.S. Drivers 
Trump Administration Unveils High-Priced “Trump Gold Card” Visa Program 
Judge Orders Return of Seized Evidence in Comey-Related Case, DOJ May Seek New Warrant 
Federal Judge Orders Restoration of SEVIS Status for Tufts PhD Student Rumeysa Ozturk 
Global Markets Slide as Tech Stocks Sink, Yields Rise, and AI Concerns Deepen 
Trump’s Approval of AI Chip Sales to China Triggers Bipartisan National Security Concerns 
U.S. Lifts Sanctions on Brazilian Supreme Court Justice Amid Shift in Brazil Relations 
BOJ Expected to Deliver December Rate Hike as Economists See Borrowing Costs Rising Through 2025 
Asian Stocks Rally as Tech Rebounds, China Lags on Nvidia Competition Concerns 
Trump Signals Two Final Candidates for Fed Chair, Calls for Presidential Input on Interest Rates 
Australia Enforces World-First Social Media Age Limit as Global Regulation Looms 
Gold Prices Dip as Markets Absorb Dovish Fed Outlook; Silver Eases After Record High 
Ireland Limits Planned Trade Ban on Israeli Settlements to Goods Only 
U.S. President Donald Trump announced sweeping new trade tariffs Thursday evening, including a 100% levy on imported pharmaceutical products, marking one of his most aggressive moves to date in reshaping America’s trade policy. The new tariffs, set to take effect October 1, will also include a 25% duty on heavy truck imports, 50% on kitchen and bathroom fittings, and 30% on upholstered furniture.
According to Trump, the pharmaceutical tariffs will apply to all branded or patented products, though companies actively building manufacturing plants in the United States will be exempt. He specified that firms must have already broken ground or begun construction on U.S. facilities to qualify. Trump framed the move as a matter of national security and a necessary step to reduce dependency on foreign drug imports.
The United States imported over $212 billion worth of pharmaceutical products in 2024, government data shows. Trump has long criticized this reliance, arguing that it threatens U.S. security and weakens domestic industries. Earlier this year, he demanded that 17 major drugmakers lower domestic drug prices while raising them abroad to balance profits. In August, Trump warned he could hike tariffs as high as 250%, signaling the seriousness of his push for reshoring production.
The tariff threats have already spurred huge investment pledges from global pharma companies. Roche committed to investing $50 billion, while Novartis announced $23 billion in U.S. facilities. American firms including Johnson & Johnson (NYSE:JNJ) and Eli Lilly and Company (NYSE:LLY) are also ramping up domestic operations to hedge against the new trade policies.
These tariffs extend beyond pharmaceuticals, targeting industries like heavy trucks, fittings, and furniture—sectors Trump says need protection to revive U.S. manufacturing and safeguard jobs. While the full impact of these measures on trade partners remains unclear, they underscore the administration’s continued reliance on tariffs as a core tool in its economic agenda.
